Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 16/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393788 | 0.90 | GRIN1 (0.70) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL8252601 | 0.87 | GRIN1 (0.70) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL5338493 | 0.87 | CHRNA7 (0.70) | GRIN1GRIN2BHTTDRD4HTR1A | |
| SCHEMBL5333493 | 0.85 | CHRNA7 (0.60) | GRIN1GRIN2BDRD4HTR1ADRD2 | |
| SCHEMBL1388535 | 0.84 | GRIN2B (1.00) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL5157052 | 0.84 | HTT (0.84) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL6941438 | 0.83 | HTT (0.69) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL18992217 | 0.83 | HTT (0.64) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL1388305 | 0.82 | GRIN1 (0.78) | GRIN1GRIN2BHTTHPGDDRD4 | |
| SCHEMBL5339354 | 0.82 | LMNA (0.52) | GRIN1GRIN2BHTTHPGDDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | GRIN1 999/4885GRIN2B 1092/4885HTT 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.